SCHEMBL29578676

SCHEMBL29578676

COc1cc(OC)c(Cl)c(-c2cc3cnc(SC)nc3c(N3CCC(O)CC3)n2)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SUV39H2 Q9H5I1 1/20 0.36
▸ NEK2 P51955 4/20 0.35
▸ PDE5A O76074 2/20 0.35
▸ GAK O14976 1/20 0.35
▸ PLK1 P53350 1/20 0.35
▸ NEK1 Q96PY6 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ PDE4B Q07343 3/20 0.35
▸ PDE4A P27815 2/20 0.35
▸ PDE4C Q08493 2/20 0.35
▸ PDE4D Q08499 2/20 0.35
▸ PDE11A Q9HCR9 2/20 0.35
▸ PDE3B Q13370 1/20 0.35
▸ FGFR4 P22455 2/20 0.34
▸ FGFR2 P21802 1/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ TTK P33981 2/20 0.33
▸ FGFR1 P11362 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21240427 1.00 SUV39H2 (0.36) SUV39H2NEK2PDE5AGAKPLK1
SCHEMBL21240243 0.90 TTK (0.38) NEK2PLK1NEK1TP53PDE4B
SCHEMBL29578389 0.90 TTK (0.38) NEK2PLK1NEK1TP53PDE4B
SCHEMBL29578158 0.89 NOS1 (0.36) TP53PDE4BPDE4APDE4CPDE4D
SCHEMBL21240537 0.89 NOS1 (0.36) TP53PDE4BPDE4APDE4CPDE4D
SCHEMBL20331789 0.89 NOS1 (0.38) TP53PDE4BPDE4APDE4CPDE4D
SCHEMBL30045100 0.89 NOS1 (0.38) TP53PDE4BPDE4APDE4CPDE4D
SCHEMBL21252178 0.89 MEN1 (0.35) SUV39H2NEK2PDE5APLK1NEK1
SCHEMBL20331796 0.88 NOS1 (0.40) SUV39H2TP53PDE4BPDE4APDE4C
SCHEMBL20331964 0.87 PDE10A (0.36) NEK2TP53PDE3BFGFR4TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 — — US disclosed
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-11-03 — — US disclosed
EP-3524603-B1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2022-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 SUV39H2 3256/4885NEK2 2833/4885PDE5A 4233/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 SUV39H2 3271/4885NEK2 2860/4885PDE5A 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback